<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inward rectifier <z:chebi fb="120" ids="26216">potassium</z:chebi> channels of the Kir2 subfamily are important determinants of the electrical activity of brain and muscle cells </plain></SENT>
<SENT sid="1" pm="."><plain>Genetic mutations in Kir2.1 associate with <z:e sem="disease" ids="C1563715" disease_type="Disease or Syndrome" abbrv="">Andersen-Tawil syndrome</z:e> (ATS), a <z:e sem="disease" ids="C0277558" disease_type="Disease or Syndrome" abbrv="">familial disorder</z:e> leading to stress-triggered <z:hpo ids='HP_0003768'>periodic paralysis</z:hpo> and <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To identify the molecular mechanisms of this stress trigger, we analyze Kir channel function and localization electrophysiologically and by time-resolved confocal microscopy </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, we employ a mathematical model of muscular membrane potential </plain></SENT>
<SENT sid="4" pm="."><plain>We identify a novel corticoid signaling pathway that, when activated by <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi>, leads to enrichment of Kir2 channels in the plasma membranes of mammalian cell lines and isolated cardiac and skeletal muscle cells </plain></SENT>
<SENT sid="5" pm="."><plain>We further demonstrate that activation of this pathway can either partly restore (40% of cases) or further impair (20% of cases) the function of mutant ATS channels, depending on the particular Kir2.1 mutation </plain></SENT>
<SENT sid="6" pm="."><plain>This means that <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> treatment might either alleviate or deteriorate symptoms of ATS depending on the patient's individual Kir2.1 genotype </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, our findings provide a possible explanation for the contradictory effects of <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> treatment on symptoms in patients with ATS and may open new pathways for the design of personalized medicines in ATS therapy </plain></SENT>
</text></document>